XP+HER(CDDP 80mg/m2 d1 and Capecitabine 2000 mg/m2 d1-15 and Trastuzumab 8 or 6 mg/kg q3w)

2 trials

Sponsors

Herceptin Database of Shimane Prefecture, SGCSG: Shimane Gastroenterological Cancer Study Group

Conditions

untreated HER2 positive advanced gastric cancer

Phase 2

Capecitabine / Cisplatin / Trastuzumab for previously untreated HER2 positive advanced gastric cancer. -Phase II study-

RecruitingJPRN-UMIN000006591

SGCSG: Shimane Gastroenterological Cancer Study Groupuntreated HER2 positive advanced gastric cancer

Start: 2011-10-01Target: 25Updated: 2026-06-29

Capecitabine / Cisplatin / Trastuzumab for previously untreated HER2 positive advanced gastric cancer.-Phase II study-

Active, not recruitingJPRN-UMIN000006590

Herceptin Database of Shimane Prefectureuntreated HER2 positive advanced gastric cancer

Start: 2011-10-01Target: 25Updated: 2026-06-29